Imugene Historical Income Statement
| IMU Stock | 0.04 0 2.56% |
Historical analysis of Imugene income statement accounts such as Other Operating Expenses of 148 M or Total Operating Expenses of 141.8 M can show how well Imugene performed in making a profits. Evaluating Imugene income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Imugene's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Imugene latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Imugene is a good buy for the upcoming year.
Imugene |
About Imugene Income Statement Analysis
Imugene Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Imugene shareholders. The income statement also shows Imugene investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Imugene Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Imugene. It is also known as Imugene overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Imugene income statement and is an important metric when analyzing Imugene profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Imugene financial statement analysis. It represents the amount of money remaining after all of Imugene operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Imugene's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Imugene current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Imugene's Interest Income is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 4.2 M in 2024, despite the fact that EBITDA is likely to grow to (140.6 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 203.4K | 190.3K | 3.3M | 3.5M | Net Interest Income | 71.9K | 1.9M | 4.0M | 4.2M |
Imugene income statement Correlations
Click cells to compare fundamentals
Imugene Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Imugene income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 82.5K | 2.0M | 2.4M | 2.2M | 5.8M | 6.1M | |
| Interest Expense | 5.0K | 5.0K | 13.6K | 27.5K | 478.4K | 502.3K | |
| Other Operating Expenses | 14.9M | 25.7M | 50.7M | 51.3M | 140.9M | 148.0M | |
| Operating Income | (14.9M) | (25.7M) | (50.7M) | (51.3M) | (140.9M) | (133.9M) | |
| Ebit | (14.6M) | (25.7M) | (50.5M) | (49.6M) | (153.8M) | (146.1M) | |
| Ebitda | (14.6M) | (23.7M) | (48.1M) | (47.4M) | (148.0M) | (140.6M) | |
| Total Operating Expenses | 14.8M | 23.7M | 48.3M | 49.1M | 135.1M | 141.8M | |
| Income Before Tax | (14.6M) | (25.7M) | (50.5M) | (49.7M) | (154.3M) | (146.6M) | |
| Total Other Income Expense Net | (3.9M) | 7.2M | (12.8M) | 1.6M | (13.4M) | (12.7M) | |
| Net Income | (10.5M) | (18.5M) | (37.9M) | (37.9M) | (149.7M) | (142.2M) | |
| Income Tax Expense | (4.1M) | (7.2M) | (12.6M) | (11.7M) | (4.6M) | (4.4M) | |
| Total Revenue | 4.1M | 7.2M | 13.0M | 11.8M | 13.5M | 14.2M | |
| Gross Profit | 4.1M | 5.3M | 10.6M | 9.6M | (5.8M) | (5.5M) | |
| Selling General Administrative | 5.5M | 10.3M | 14.1M | 20.4M | 45.0M | 47.3M | |
| Net Income From Continuing Ops | (10.5M) | (18.5M) | (37.9M) | (39.2M) | (149.7M) | (142.2M) | |
| Research Development | 9.4M | 15.4M | 36.6M | 30.9M | 86.9M | 91.2M | |
| Cost Of Revenue | 82.5K | 2.0M | 2.4M | 2.2M | 5.8M | 6.1M | |
| Net Income Applicable To Common Shares | (10.5M) | (18.5M) | (37.9M) | (37.9M) | (34.1M) | (32.4M) | |
| Selling And Marketing Expenses | 82.5K | 154.8K | 334.9K | 506.5K | 582.5K | 305.7K | |
| Interest Income | 297.2K | 126.6K | 192.2K | 1.9M | 4.5M | 4.7M | |
| Net Interest Income | 297.2K | 10.5K | 71.9K | 1.9M | 4.0M | 4.2M | |
| Reconciled Depreciation | 82.5K | 104.2K | 203.4K | 190.3K | 3.3M | 3.5M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.